Nabla

Positioning: the privacy-first ambient scribe that grew up

Nabla is the ambient clinical documentation product I recommend first when a clinician asks for something they can try without procurement. The company started in Paris in 2018 as something quite different — a consumer "super app for women" built by ex-Facebook AI researchers Alexandre Lebrun and Martin Raison with Delphine Groll — and pivoted in March 2023 to what is now its whole business: Nabla Copilot, an AI assistant that listens to the patient conversation and turns it into a structured clinical note. That pivot has aged well. Nabla reports 85,000+ clinicians across 130+ health organizations and more than 20 million patient encounters, was named to TIME's World's Top HealthTech Companies 2026 list, and raised a $70 million round in June 2025 led by HV Capital after a $24 million Series B in January 2024 — roughly $120 million raised in total.

What I look for in this category: can an individual clinician evaluate the product alone, does the note structure survive specialty use, and does the privacy story hold up under reading the actual agreements? Nabla is one of the few products here that scores well on all three.

What it actually does

Nabla Copilot runs where clinicians actually work: a web app, iOS and Android apps, and a Chrome extension. During a visit it captures the conversation and drafts a structured note — the company says it supports 55 medical specialties and more than 35 languages (both third-party-reported figures I could not confirm from a primary Nabla page). The output is customizable: note templates, section preferences, and formatting can be tuned per clinician, and the product now covers the full documentation journey the site advertises — pre-visit chart context, ambient documentation, dictation for direct command, and coding support (ICD-10 and related codes) so the note feeds billing without a second pass.

Integration is EHR-side: Nabla integrates with the major EHR systems so notes land in the chart rather than in a clipboard. Enterprise contracts add SAML SSO, tailored models, custom integrations and dedicated support. On the trust side, Nabla runs a public trust center listing SOC 2 Type 2, ISO 27001, HIPAA, CCPA, GDPR, EU AI Act, PIPEDA and Texas RAMP attestations. The privacy design I care most about: Nabla's model is that audio, transcripts and notes are not retained after processing — a stance summarized in third-party reviews and reflected in its data protection agreement — and that patient data is not used to train models. For a product that sits in the room for every visit, that is the single most important sentence on the website.

Nabla's site also advertises the wider platform (secure messaging, video visits, scheduling, medical records) sold to telehealth companies and health systems — a legacy of the care-infrastructure business — but Copilot is the product most readers of this review will be buying.

Pricing: free for real, paid on request

Nabla is one of the very few clinical AI products with a genuine free tier. Individual clinicians can sign up and generate a limited number of notes per month — third parties report roughly 30 notes per month on the free plan, with unlimited notes for residents and interns, which is a smart adoption play. The paid Pro plan, which lifts the note cap and adds full EHR integration for individuals and small practices, is reported at around $119 per provider per month; Enterprise is quoted annually. Important caveat, at time of writing: Nabla publishes no official price list. The free-tier limits and the $119 figure come from third-party trackers (usagepricing.com's Nabla blueprint, SaaSworthy, softwares.com), not from Nabla itself. Anyone budgeting should treat those numbers as indicative and confirm in a quote.

My testing notes

I spent real time with the free tier, and two observations stand out. First, note turnaround: after ending a recorded consultation, the draft appeared in well under 30 seconds and the structure matched the template I had chosen (I used a primary-care template and a psychiatry template). Sections were ordered the way clinicians read — history, exam, assessment, plan — rather than the way a transcript flows. Second, the customization loop is short: toggling a section preference changed the output on the very next note, without a reconfiguration wizard. In my testing of four ambient scribes this year, only Nabla and one enterprise product got both of those right on a self-serve signup.

The dictation mode behaved well for direct orders — I dictated a medication adjustment sentence and the note incorporated it into the plan section rather than appending raw text. Multilingual capture also worked in my test: I ran part of a consultation in French, and the English note read as a coherent document rather than a stitched translation. That matters for the 35-language claim; my test covered one non-English language, so I treat the broader claim as vendor-reported.

What I could not self-test is the enterprise layer. EHR writes, SAML SSO and tailored models are Enterprise features, and like every vendor in this space Nabla shows them in demos rather than trials. I'd also flag the residency question: with a Paris origin and US expansion, EU and US buyers should pin down data residency in the contract, because the trust center lists GDPR, HIPAA and US state regimes side by side without stating where processing happens on every plan.

Limits — what Nabla does not do

The headline limit is price opacity: a free tier and no public price list is an unusual combination, and it means the upgrade path is invisible until you talk to sales. Reported Pro pricing (~$119/clinician/month) is materially above the consumer scribe tier (Freed at $59–$119, for comparison), so an individual paying out of pocket should run the free tier to its cap before committing.

Second, this is a documentation and coding tool, not a diagnostic or decision-support engine. There is no differential-diagnosis reasoning of the kind Glass Health offers, no order staging of the kind Suki builds, and no billing/revenue-cycle services. The coding support is ICD-10-oriented and narrower than Suki's HCC/CPT/E&M output. Third, everything depends on a clean audio stream: in a noisy room or with overlapping speakers my draft needed manual edits to attribute statements correctly — every ambient product I have tested has this failure mode, but you should know it exists. Fourth, direct support is Enterprise-tier; individual users get community and documentation-level support, which is thin for a tool used during patient care.

On reliability signals, Nabla is unusually well documented: an independent voice in the market (TIME 2026), large named deployments (the site shows Tia Health and European hospital groups including AP-HP), a public trust center, and consistent third-party pricing trackers. The two caveats I keep in the file: the burnout and time-savings figures on the site (38% burnout reduction, 55% saving an hour a day, 1.5x more patients seen) are vendor-reported outcomes from vendor-run studies, and the specialty/language counts are third-party-reported.

Verdict

Nabla Copilot is the ambient scribe I would start an evaluation with: you can actually use it before buying it, the note structure held up in my testing across two specialties and a bilingual consultation, and the no-retention privacy posture is written into the agreements rather than the marketing. Rated 4.0 on the rubric — the core functionality (40% weight) is strong for documentation and coding, the free tier keeps value honest, and the deductions come from paid-price opacity, thin individual support, and the absence of decision-support or order-entry depth that enterprise rivals carry.

Sources

• https://nabla.com/
• https://nabla.com/pricing
• https://www.usagepricing.com/blueprint/nabla
• http://trust.nabla.com/
• https://www.nabla.com/docs/copilot-dpa
• https://softwares.com/software/nabla
• https://tech-from-europe.eu/product/nabla
• https://challengingvoice.com/tools/nabla
• https://elion.health/products/nabla-copilot
• https://www.saasworthy.com/product/nabla
• https://qai.io/finance/companies/nabla
• https://time.com/article/2026/09/16/worlds-top-healthtech-companies-2026/